Resmetirom is a thyroid hormone receptor beta (THR-β) agonist used in conjunction with diet and exercise in the therapy of nonalcoholic steatohepatitis (NASH) with moderate-to-severe fibrosis. Resmetirom therapy is associated with mild and transient serum aminotransferase elevations during the first month of therapy and with rare instances of acute liver injury which can be severe, but which reverses on drug discontinuation.
Resmetirom是一种甲状腺激素受体β（THR-β）激动剂，与饮食和运动联合用于治疗伴有中重度纤维化的非酒精性脂肪性肝炎（NASH）。Resmetirom治疗在治疗的第一个月与轻度和短暂的血清转氨酶升高有关，并且罕见急性肝损伤病例，这种损伤可能很严重，但停药后可逆转。
